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Clinics 
Age and sex: 10 years old male patient. 
Previous History:  
- no preleukemia;  
- no previous malignant disease;  
- no inborn condition of note.  
Organomegaly:  
- hepatomegaly;  
- no splenomegaly;  
- no enlarged lymph nodes;  
- no central nervous system involvement 
Blood 
WBC: 34 x 109/l; Hb: 8,2 g/dl; platelets: 57x 109/l; 
blasts: 92% 
Bone marrow: 94% 
Cytopathology classification 
Cytology: M2 without Auer rods; Peroxidase (+) 
esterase (+). 
Immunophenotype: CD13+, CD33+ 
Pathology: - 
Electron microscopy: - 
Precise diagnosis: ANLL M2 
Survival 
Date of diagnosis: 06-2007. 
Treatment: AML BFM Protocol (high risk). 
Complete remission was obtained. 
Treatment related death: - 
Relapse: - 
Status: Alive 09-2007. 
Karyotype 
Sample: Bone Marrow;  
Culture time: two cultures 48 hours;  
Banding: GTG-Banding. 
Results: 46,X,-Y,+8,t(16;21)(q24;q22) 
Other molecular studies 
Technics: FISH evaluation for AML1 rearrangement 
and trisomy 8 was performed on abnormal metaphases 
after 48h of cultivation with the LSI AML1/ETO Dual 
Color Probe (Abbott Molecular/Vysis, Inc.).  
Results: ish +8(ETO x 3), der(16)t(16;21) 
(dimAML1+), der(21)t(16;21) (dimAML1+) 
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GTG-banded chromosomes which are representing the trisomy 8 and the t(16;21). 
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Comments 
The t(16;21)(q24;q22) is a rare aberration in AML with 
16 cases described in the Mitelman-database and it is 
extreme rare in children (only two cases published). 
Most of these 16 cases are classified to the FAB M2 
subtype and a trisomy 8 was seen as a recurrent 
secondary aberration of t(16;21). Loss of one sex 
chromosome as a secondary aberration of t(16;21) has 
not been described yet. This is to our knowledge the 
first case of an AML with t(16;21)(q24;q22), trisomy 8 
and loss of the Y-chromosome. The specific aberration 
for AML M2 is the t(8;21)(q22;q22), which shows 
often a loss of one sex chromosome (seen in 50% of the 
cases) and in 10% a trisomy 8 as secondary aberrations 
(Huret, 1997). Maybe the t(16;21)(q24;q21) is a rare 
equivalent of the t(8;21), because 1) the same gene 
RUNX1, located on (21)(q22), is involved and has 
similar genes as translocation partners: RUNX1T1 
(ETO) in the t(8;21) and CBFA2T3 in the t(16;21); 
both are coding for ETO proteins, 2) the t(16;21) 
occurs often in cases with the same AML M2 
morphology, and 3) patients with t(16;21) show the 
same additional chromosome anomalies (-Y/+8). While 
trisomy 8 is quite frequent in various leukemias the loss 
of the Y chromosome is a very specific secondary 
aberration of the t(8;21). This is the second described 
case of a de novo AML M2 with t(16;21)(q24;q22) in 
childhood AML (Jeandidier et al., 2006). 
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